

Pioneering a New Class of Cell-Based Therapeutics



HOPE Neuron
Therapeutics

A non-drug, immune-reprogramming device-enabled platform for ALS, and other autoimmune neurodegenerative diseases.

June 2026

Disclaimer

This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to an investment of securities in Hope-Neuron therapeutx, Inc, a Delaware corporation (the "Company", "we", "our" and "us") and for no other purpose. This presentation is strictly confidential and is being furnished solely in reliance on applicable exemptions from the registration requirements under the U.S. Securities Act of 1933 (the "Act"). This presentation does not contain, nor does it purport to contain, a summary of all the material information concerning the Company or the terms and conditions of any potential investment in the Company. The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.

The securities to be offered have not been approved or disapproved by the U.S. Securities and Exchange Commission (the "SEC"), or any other securities regulating body or agency, nor has any such authority, commission, or body passed on the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offense. The securities will be subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under the Act and applicable state securities laws pursuant to registration or exemption therefrom. Investors should be aware that they may be required to bear the financial risks of an investment in the securities for an indefinite period of time. The securities will not be listed on any securities exchange or automated quotation system, and there is no obligation on the part of any person to make a market for the securities. No action has been made or will be taken that would permit a public offering of any securities in any jurisdiction in which action for that purpose is required. No offers, sales, resales or delivery of any securities or any distribution of any offering material relating to any securities may be made in or from any jurisdiction except in circumstances which will result in compliance with any applicable laws and regulations and which will not impose any obligation on the Company.

If and when you determine to proceed with discussions and investigations regarding a possible investment in the Company, you are urged to carry out independent investigations in order to determine your interest in investing in the Company. This presentation and any oral statements made in connection with this presentation are for informational purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any securities of the Company. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting or other advice.

Forward-Looking Statements:

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 ("PSLRA"), including statements regarding our relationships with our partners, liquidity issues and risks inherent in funding, developing and obtaining regulatory approvals of commercially-viable and competitive products and treatments, the intent, belief or current expectations of us and members of our leadership team, as well as the assumptions on which such statements are based. Words such as "expects," "plans," "predicts," "projects," "will," "may," "anticipates," "seeks," "potential," "believes," "should," "intends," "would," "could," "estimates," or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to risks, uncertainties, and other factors, many of which are outside our control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. Further, forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update or revise any forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Industry and Market Data:

Industry and market data used in this presentation have been obtained from third party industry publications and sources, including reports by market research firms. The Company has not independently verified the information and data obtained from these sources and cannot assure you of the data's accuracy or completeness. This information and data is subject to change.



Our Discovery: Could be the First Effective Treatment for ALS

Backed by results from our proof-of-concept mouse study, we are now just months away from human ALS trials -- where success would create a new category of therapeutics and unlock multibillion dollar market opportunities.



Our Empathy Comes from Experience



A Personal Mission


Our company has noble roots, the culmination of more than a decade of research first started by founder Ronald Lane in an effort to save his wife Sandy Elizabeth Lane from Alzheimer's.

We honor her memory in our SELtx™ technology name, which also serves as a reminder of our personal empathy for families dealing with neurological disease.




Our Focus: Countering the Root Cause of Autoimmune Dysfunction

Autoimmune conditions share a common mechanism of action – a person's immune system mistakenly attacks the body's own healthy cells, tissues and organs.




Our Novel Solution: SELtx™

A 30-minute, outpatient, blood-processing therapy that triggers apoptosis (cell death) to restore immune balance by shifting M1 “killer” cells to M2 “healer” cells.



Draw



Process



Reinfuse

1. Whole blood drawn (-300mL) in sterile, disposable vials
2. Hyperoxic stress triggers apoptosis in our patented device
3. Treated reinfused blood stimulates efferocytosis (anti-inflammatory cell removal) and immune rebalancing



Our first target is ALS

Amyotrophic lateral sclerosis (ALS) is brutal,
destroying muscle function while the mind remains intact.

every 90

minutes, someone is diagnosed—and
someone dies—from ALS.


2-5

years median survival

90%

of ALS cases are sporadic with no known
cause.

A condition with a famous name (Lou Gehrig's disease),
one of the greatest viral campaigns in marketing history
(The Ice Bucket Challenge), \$2B+ spent seeking a cure,
but no effective therapy.



The Defining Moment: Stunning Preclinical Results

Our ALS-infected transgenic mice study set new benchmarks.

Highlights:


Mice treated with SELtx™ preserved significant motor function

Confirmed M1 → M2 immune shift ($p < 0.008$)

Untreated ALS mice fell off the treadbar and showed disease progression

SELtx™ treated mice continued to live and run, run, run

**We didn't just slow decline,
*we reversed it***



SELtx™ has industry-leading potential in terms of cost, side effects and efficacy.

ALS Therapy	Annual Cost	Median Survival Benefit
SELtx™	\$120,000	Est. 4+ years
Side Effects	None Identified	
Edaravone (Radicava)	\$171,000	7.3 months
Side Effects	Life-threatening anaphylaxis, sulfite allergy, gait disturbance, respiratory failure, skin reactions ...	
Tofersen (Qalsody) *	\$185,000	3.4 years
Side Effects	Back, limb, and joint pain; fatigue, and elevated white blood cells in cerebrospinal fluid	

**Tofersen is only usable in about 2% of the ALS population.*

Competitive Landscape

Overview

- Pharma has spent over \$2B failing to deliver a durable ALS solution
- Amylyx, Biohaven, UCB, Clene, Denali, PTC, and Corcept all failed endpoints (2024-2025)
- There are currently more than 50 ALS-focused research studies targeting drug-based solutions for ALS - indicative of the urgent need.



Market Need and Opportunity

Our initial target market is ALS, with potential revenue of \$1.8 billion by Dec 2028 and overlapping neurodegenerative mechanics that could lead to new indications.

HOPE-Neuron's Allocation & Critical Path Sensitivity

Assumed target patient population by year end 2028: **ALS 34,000 Patients**

Projected Revenue Allocation

- 40% HOPE-Neuron
- 35% Provider
- 25% Distributor


Opportunity Timeline

First target ALS (&FDA approval submission) in partnership with leading US clinics.


Gross Treatment Revenue

Estimated \$40,000 per treatment, 3 treatments/year, Annual total: \$120,00/Patient

SELtx™ ALS Estimates Cross the \$1.0B Annual Revenue Threshold Even at Modest Penetration Rates



Beyond ALS - Much Larger Markets



“One More Thing” Times X

Positive results in our IRB will open research avenues (see chart) in markets that are exponentially larger than ALS.

Top Tier Margins and Scalability

As a platform technology, our device can be used for a host of disease states - maximizing profit margins as the network grows.

Open-Ended Science

The NIH estimates that there are more than 100 diseases with an autoimmune component - opening the door for **Compassionate Use**, **Right to Try**, and additional studies beyond our initial targets.

Condition	ALS	Alzheimer's	Cancer	MS	Parkinson's
Revenue Estimate (Billions)	1.4	28.8	43.2	6.0	6.6
Target Patient Population	34,000	8,000,000	18,000,000	1,000,000	1,100,000
Market Penetration	35%	3%	2%	5%	5%


All figures are estimates based on low-to-mid-range penetration rates for U.S. patient populations.



Our Roadmap is Set

The next stage starts within days after funding

- IRB human trial and research partners identified and in place: Banner, Barrow, Indiana University School of Medicine
- Transgenic mouse (n=10 ALS) and *human IRB results possible in less than 12 months*
- First Step - \$5M Reg CF will fund pivotal studies for commercial launch
- Future Reg A+ will provide liquidity event and up to \$75M for corporate development, technology & patent expansion, plus target expansion.



Military veterans and firefighters are roughly twice as likely to develop ALS compared to the general population. Due to this increased risk, the U.S. Department of Veterans Affairs (VA) classifies ALS as a presumptive service-connected disease.

SELtx™



 Banner Health.




Partnerships: Our Key to Growth

Rapid expansion in an unserved market will require partners with established networks.

Strategy

- Currently curating potential operational partners to support a national network of SELtx™ devices.
- Manufacturing partner already in place with capacity for global footprint.
- Various revenue sharing models under consideration, with conservative 40% share for HOPE-Neuron and est. gross margins at scale in excess of 85%.



Projected revenue allocation

40%

HOPE-Neuron*

35%

Provider

25%

Distributor*

*includes:

Recurring revenue from consumables and disposables

Optional licensing model for global partnerships



Valuations in Our Space are Measured in \$Billions

Recent Comps

\$400M – the annual run rate after just four quarters for ALS drug *Relyvrio (Amylyx)*, before the drug was pulled from the market in 2024.

\$925M – the acquisition price tag in 2024 for *Therakos*, our closest (non-ALS) technology comp.

\$2.5B – the price Shionogi & Co. Ltd paid in April 2026 for global rights to the leading ALS drug *Radicava (edaravone)* with \$700M in annual sales.

Massive Unserved Market

13 – The number of Quality-Adjusted Life Years (QALY) lost per ALS patient.

\$2.5B – annual healthcare cost of ALS in the U.S. alone

\$3.14B – estimated annual value of halting disease progression in the U.S.


\$26B-\$40B – Estimated commercial value of a successful ALS treatment in the U.S.

Source: Office of Health Economics (OHE)

Currently approved treatments for ALS generally prolong life by only 2 to 19 months, and focus on slowing disease progression without improving a patient's health. The bar is set low for HOPE-Neuron's therapy, which demonstrated the ability to nearly "freeze" disease progression while maintaining motor function.



Well Defined Comps & Milestones



Large Underserved Markets

HOPE-Neuron operates in a field where even modestly effective therapies generate multi-billion-dollar valuations.

Compelling Comps

Our comp valuations are highly correlated with our business, set within the last three years and rising.

Compressed Timeline


HOPE-Neuron's IRB trial is designed to produce actionable data within weeks of first human testing.

Key: As a device-enabled therapy, our path to market is accelerated compared to drug-based solutions.

*Development phase valuations are estimates from 2025 third-party rNPV analysis sources.



Our Technology Development Timeline



Pre-2022	2023-2024	2025	2026 Goals
----------	-----------	------	------------

Laying the Groundwork

- Identified immune dysfunction as a key therapy target in neurodegeneration
- Fabricated and tested first-generation device

Proof of Concept

- Explored the use of the SELtx™ device for ALS therapy
- Validated M1-to-M2 immune shift in ALS mouse models

Planning Phase

- Designed pivotal human IRB and mouse trials
- Expanded team and resources to support rapid business growth

Path to Commercialization

- Construct next generation SELtx™ device
- Conduct IRB human trial and dosing optimization mouse studies
- Prepare study targeting Alzheimer’s



Mission-Led. Expert-Driven



Ronald Lane, PhD

**Founder &
Executive Chairman**

Neurobiologist and
inventor of the SELtx™
platform.



Yansheng Du, PhD

**Lead, Preclinical
Transgenic Research**

Professor of Neurology,
Indiana University School
of Medicine.



Mark Forney

**VP of Business
Development**

Specializing in high-
growth, scalable
technology applications



Karina Fedasz

Interim CFO

Leads regulatory
and registration
efforts.



John Louf

**Chief Technology
Officer**

Leads technology
infrastructure, operations,
and IP expansion.



Intellectual Property & Defensibility

Globally protected technology targeting immune modulation.

Patents granted and pending across U.S., Japan, Canada, India, Australia

Covers proprietary hyperoxia gas-fluid contact reactor and mechanotransduction process

Future filings planned for device development and optimization

U.S. Patent No. 1171579 “GAS TREATMENT DELIVERY SYSTEMS AND METHODS”/October, 2022



Japan Patent No. 75297259 “GAS TREATMENT DELIVERY SYSTEMS AND METHODS”/July, 2024



U.S. Patent No 7,736,494 B2 Method of Use “OZONE DELIVERY SYSTEM INCLUDING A VARIABLE PITCH GAS-FLUID CONTACT DEVICE”



Int’l Pat App: PCT/US2010/001785 “TREATMENT OF INFLAMMATORY DISORDERS, CARDIOVASCULAR DISEASES AND ACUTE ISCHEMIC BRAIN STROKE WITH OZONE”



Int’l Pat App: PCT/US2017/047690 “GAS TREATMENT DELIVERY SYSTEM AND METHODS” (China, India, Canada, Australia)



Our Pivotal Moment Has Arrived


What We Know

- SELtx™ is the most effective ALS therapy to date in animal studies.
- Our technology can return a body to homeostasis by rebalancing M1 and M2 cells.
- Our therapy appears to be well tolerated and has an excellent side effect profile.

The Questions We Plan To Answer in Our Upcoming Trials

- How well will SELtx™ translate to humans?
- What is the ideal therapy regimen and dosing level?
- Will SELtx™ be just as effective in other disease states?

Our technology doesn't fight millions of years of evolution, but simply returns a body to a state where it can heal itself.





HOPE Neuron
Therapeutx

The Impact: Our upcoming industry-first human trial has the potential to become a watershed moment in the treatment of neurodegenerative disease.

Please Join Us as We Work to Bring HOPE to the ALS Community

Contact:

hope@hopeneuron.com

Website:

www.hopeneuron.com

Hope-Neuron Therapeutx Inc. is a U.S. Corporation with operations in Arizona, California, and Indiana